Status:
UNKNOWN
High Flow Nasal Cannula and Hypercapnia
Lead Sponsor:
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Conditions:
COPD
Eligibility:
All Genders
18-85 years
Phase:
NA
Brief Summary
In the present investigation, in 50 COPD with persistent hypercapnia after an acute exacerbation, the investigators want to assess the acceptability of HFNC and its effectiveness in further reducing t...
Detailed Description
Fifthy COPD patients inpatients recovering from an acute exacerbation of their disease and persisting hypercapnia, despite having reached a stabilization in pH (i.e. pH\>7,35 and PaCO2\>45 mmHg on 3 c...
Eligibility Criteria
Inclusion
- inpatients recovering from an acute exacerbation of their disease
- persisting hypercapnia, despite having reached a stabilization in pH (i.e. pH\>7,35 and PaCO2\>45 mmHg on 3 consecutive measurements)
Exclusion
- Cardiac decompensation,
- restrictive thoracic disorders,
- renal insufficiency,
- cancer,
- neurological disease
Key Trial Info
Start Date :
November 29 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 29 2019
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT03759457
Start Date
November 29 2018
End Date
January 29 2019
Last Update
November 30 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sant'Orsola Hospital
Bologna, Italy, 40138